RobertMDeanMD

PubMed

• BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA.
  Singer, S.,Dean, R.,Zhao, Q.,Sharma, N.,Abounader, D.,Elder, P.,Hofmeister, C. C.,Benson, D. M.,Rosko, A.,Penza, S.,Andritsos, L.,Vasu, S.,Jaglowski, S.,William, B. M....> ;Biol. Blood Marrow Transplant.. 2019 Feb 05
• BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
  Singer, S.,Sharma, N.,Dean, R.,Zhao, Q.,Abounader, D.,Elder, P.,Hofmeister, C. C.,Benson, D. M.,Rosko, A.,Penza, S.,Andritsos, L.,Vasu, S.,Jaglowski, S.,William, B. M....> ;Bone Marrow Transplant.. 2019 Feb 06
• Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
  Chakraborty, R., Chakraborty, R., Chakraborty, R., Liu, H. D., Liu, H. D., Liu, H. D., Rybicki, L., Rybicki, L., Rybicki, L., Tomer, J., Tomer, J., Tomer, J., Khouri, ...> ;American journal of hematology. 2019 Jan 22
• Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
  Radivoyevitch, T.,Dean, R. M.,Shaw, B. E.,Brazauskas, R.,Tecca, H. R.,Molenaar, R. J.,Battiwalla, M.,Savani, B. N.,Flowers, MED.,Cooke, K. R.,Hamilton, B. K.,Kalaycio,...> ;Leuk. Res.. 2018 Jul 30
• Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
  Winter, A.,Rybicki, L.,Shah, S. N.,Jagadeesh, D.,Gerds, A. T.,Hamilton, B. K.,Liu, H.,Dean, R.,Sobecks, R.,Pohlman, B.,Smith, M.,Kalaycio, M.,Bolwell, B. J.,Majhail, N...> ;Leuk. Lymphoma. 2017 Aug 31
• A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.
  Hill, B. T.,Smith, M. R.,Shelley, M.,Jagadeesh, D.,Dean, R. M.,Pohlman, B.,Sweetenham, J. W.,Bolwell, B. J.,Smith, S. D.> ;Leuk. Lymphoma. 2017 Jul 12
• Prognostic Factors for Mortality among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation.
  Patel, S. S.,Rybicki, L. A.,Corrigan, D.,Bolwell, B.,Dean, R.,Liu, H.,Gerds, A. T.,Hanna, R.,Hill, B.,Jagadeesh, D.,Kalaycio, M.,Pohlman, B.,Sobecks, R.,Majhail, N. S....> ;Biol. Blood Marrow Transplant.. 2018 Jan 26
• 2 citations
  Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
  Adam G. Starr, Paolo F Caimi, Pingfu Fu, Mira R. Massoud, Howard J. Meyerson, Eric D. Hsi, David B. Mansur, Sheen Cherian, Brenda Cooper, Marcos de Lima, Hillard M. La...> ;Hematology. 2017 Jan 20
• 1 citations
  GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies
  Aziz Nazha, Lisa Rybicki, Donna Abounader, Brian J. Bolwell, Robert M. Dean, Aaron T. Gerds, Deepa Jagadeesh, Betty K. Hamilton, Brian T. Hill, Matt Kalaycio, Hien K. ...> ;Bone Marrow Transplantation. 2016 Oct 10
• 3 citations
  Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
  Adam G. Starr, Paolo F Caimi, Pingfu Fu, Mira R. Massoud, Howard J. Meyerson, Eric D. Hsi, David B. Mansur, Sheen Cherian, Brenda Cooper, Marcos de Lima, Hillard M. La...> ;British Journal of Haematology. 2016 Oct 1
• Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.
  Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS> ;Bone Marrow Transplant.. 2016-09-01
• Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autol...
  Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, Liu H, Dean R, Sobecks R, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS> ;Biol. Blood Marrow Transplant.. 2016-09-01
• Is rituximab sub-optimally dosed in indolent B cell lymphoma?
  Sawalha Y, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D, Pohlman BL, Smith MR> ;Br. J. Haematol.. 2016-09-01
• Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment ...
  Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, Morgan DS, Greer JP, Smith MR, Hill BT, Reddy NM> ;Br. J. Haematol.. 2016-07-13
• Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
  Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS> ;Biol. Blood Marrow Transplant.. 2016-06-01
• Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
  Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM...> ;Br. J. Haematol.. 2016-05-01
• Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.
  Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, Gerds A, Hamilton BK, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Liu HD, Pohlman B, Sobecks RM, Majhail NS> ;Bone Marrow Transplant.. 2015-10-01
• Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.
  Hamilton BK, Law AD, Rybicki L, Abounader D, Dabney J, Dean R, Duong HK, Gerds AT, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Lawrence C, McLellan L, Pohlman B, Sobec...> ;Bone Marrow Transplant.. 2015-09-01
• Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites.
  Hamilton BK, Rybicki L, Sekeres M, Kalaycio M, Hanna R, Sobecks R, Dean R, Duong H, Hill BT, Bolwell B, Copelan E> ;Bone Marrow Transplant.. 2015-06-01
• 14 citations
  Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor alloge...
  Betty K. Hamilton, Lisa A. Rybicki, Robert M. Dean, Navneet S. Majhail, Housam Haddad, Donna Abounader, Rabi Hanna, Ronald Sobecks, Hien K. Duong, Brian T. Hill, Edwar...> ;American Journal of Hematology. 2015 Feb 1
• Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.
  Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA> ;Bone Marrow Transplant.. 2014-11-01
• Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
  Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR> ;Biol. Blood Marrow Transplant.. 2013-10-01
• Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.
  Sobecks RM, Rybicki L, Yurch M, Kalaycio M, Dean R, Andresen S, Pohlman B, Duong H, Bolwell B, Copelan E> ;Bone Marrow Transplant.. 2012-05-01
• Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patient...
  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR> ;J. Clin. Oncol.. 2012-03-10
• Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.
  Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E> ;Bone Marrow Transplant.. 2012-02-01
• Join now to see all

Abstracts/Posters

• Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
  Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
  Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
  Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018